Want to see EKTAY full AI Analyst Report?
EKTAY Stock Chart & Stats
$5.92
$0.14(3.03%)
At close: 4:00 PM EDT
$5.92
$0.14(3.03%)
Day’s Range― - ―
52-Week Range$4.42 - $6.88
Previous CloseN/A
Volume3.81K
Average Volume (3M)3.66K
Market Cap
$2.09B
Enterprise Value$2.42K
Total Cash (Recent Filing)$2.30B
Total Debt (Recent Filing)$6.81B
Price to Earnings (P/E)―
Beta1.33
Next Earnings
Nov 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield4.76%
Share Statistics
EPS (TTM)-0.98
Shares Outstanding368,587,650
10 Day Avg. Volume1,146
30 Day Avg. Volume3,664
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)2.92
Price to Sales (P/S)1.26
P/FCF Ratio8.98
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationStrong operating and free cash flow provides internal funding for R&D, debt service and investment. Cash generation exceeding accounting earnings also supports resilience during the turnaround, although working-capital movements remain a monitoring point.
Structural Cost Savings And Margin RecoveryCompleted restructuring and recurring savings can improve the cost base beyond a single quarter. Headcount reductions and regional accountability should support operating leverage, while higher software and service mix may make margin gains more durable.
Recurring Service Revenue And Installed-base StrengthService, maintenance and software tied to Elekta’s installed systems create recurring revenue that is less dependent on new equipment orders. Broad-based service growth improves revenue visibility and can support margins as the installed base expands.
Bears Say
Severe Revenue Decline And Negative ProfitabilityThe sharp revenue contraction and return to net losses indicate materially weaker operating leverage and execution than in prior profitable years. Even with stable gross margin, restoring sustainable growth and earnings remains a central medium-term risk.
Regional And Order-intake WeaknessWeak solutions demand and uneven regional orders constrain equipment revenue and can delay backlog conversion. China’s depleted backlog, procurement pressure and lower market share may prolong recovery, limiting Elekta’s ability to capture a growing market.
Higher Leverage And Cost PressuresGreater leverage reduces financial flexibility while the earnings decline weakens returns on the capital base. Component inflation, tariffs and more conservative R&D accounting could also offset restructuring benefits and make margin recovery less predictable.
Elekta AB News
EKTAY FAQ
What was Elekta AB’s price range in the past 12 months?
Elekta AB lowest stock price was $4.42 and its highest was $6.88 in the past 12 months.
What is Elekta AB’s market cap?
Elekta AB’s market cap is $2.09B.
When is Elekta AB’s upcoming earnings report date?
Elekta AB’s upcoming earnings report date is Nov 25, 2026 which is in 79 days.
How were Elekta AB’s earnings last quarter?
Elekta AB released its earnings results on Aug 27, 2026. The company reported $0.073 earnings per share for the quarter.
Is Elekta AB overvalued?
According to Wall Street analysts Elekta AB’s price is currently Overvalued.
Does Elekta AB pay dividends?
Elekta AB pays a Semiannually dividend of $0.127 which represents an annual dividend yield of 4.76%. See more information on Elekta AB dividends here
What is Elekta AB’s EPS estimate?
Elekta AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Elekta AB have?
Elekta AB has 368,587,650 shares outstanding.
What happened to Elekta AB’s price movement after its last earnings report?
Elekta AB reported an EPS of $0.073 in its last earnings report. Following the earnings report the stock price went down -2.817%.
Which hedge fund is a major shareholder of Elekta AB?
Currently, no hedge funds are holding shares in EKTAY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Elekta AB Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
EKTAY Sentiment 100%
Sector Average 60%
Sector Average 60%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
19.22%
12-Months-Change
Fundamentals
Return on Equity
4.76%
Trailing 12-Months
Asset Growth
-6.37%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Elekta AB
Elekta AB (publ) is a global medical technology company dedicated to developing and delivering advanced clinical solutions for the treatment of cancer and brain disorders. Its comprehensive portfolio includes innovative radiotherapy systems such as the Elekta Unity MR-Linac, the Elekta Harmony linear accelerator, Elekta Infinity for diverse patient radiotherapy requirements, and the Elekta Synergy digital accelerator for advanced image-guided radiation therapy. Specific solutions like Versa HD are available for managing brain metastases. The company also supplies crucial treatment management software, automated and integrated quality assurance tools, and hardware and software for motion management. Further augmenting its oncology offerings, Elekta provides MOSAIQ Plaza for integrated multidisciplinary cancer care and Elekta Axis Cloud for managed hosting. Within brachytherapy, key products include the image-guided Elekta Studio, the mobile ImagingRing CT scanner, Oncentra Brachy for streamlining repetitive tasks, the Elekta Flexitron afterloader for precise workflow execution, and specialized applicators like Venezia and Geneva for cervical cancer treatment. For neurological conditions, Elekta offers a suite of advanced radiosurgery and neurosurgery solutions. This includes the Leksell Gamma Knife series – Icon for personalized radiation treatment, Perfexion for neurosurgical applications, and Lightning for accelerated procedures. Its neurosurgery product line features the Leksell Vantage Stereotactic System for intracranial interventions and the Leksell Stereotactic System for minimally invasive stereotactic neurosurgery. Founded in 1972, Elekta maintains its corporate headquarters in Stockholm, Sweden.
EKTAY Company Deck
EKTAY Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balanced picture: strong execution on cost savings and clear improvements in margins and cash generation provided encouraging evidence that the company’s turnaround is underway. However, top‑line challenges remain — net sales declined, solutions sales were weak, China and APJ showed regional softness, rolling orders lagged and working capital rose. Management reaffirmed FY guidance and expects Q2 revenue improvement driven by backlog and U.S. product momentum. Overall the company appears to be stabilizing and improving profitability while still working through material revenue and regional challenges.View all EKTAY earnings summariesTechnical Analysis
Ownership Overview
―
Insiders
0.02% Mutual Funds
<0.01% Other Institutional Investors
99.97% Public Companies and
Individual Investors